Using iRFP Genetic Labeling Technology to Track Tumorogenesis of Transplanted CRISPR/Cas9-Edited iPSC in Skeletal Muscle

  • Yue Jin
  • Yan Shen
  • Neal L. Weintraub
  • Yaoliang TangEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 2126)


Tumorigenesis and attendant safety risks are significant concerns of induced pluripotent stem cell (iPSC)-based therapies. Thus, it is crucial to evaluate iPSC proliferation, differentiation, and tumor formation after transplantation. Several approaches have been employed for tracking the donor cells, including fluorescent protein and luciferase, but both have limitations. Here, we introduce a protocol using iRFP genetic labeling technology to track tumor formation of iPSCs in skeletal muscle after CRISPR/Cas9 gene editing.

Key words

Infrared fluorescent protein (iRFP) Induced pluripotent stem cells (iPSC) Tumor formation CRISPR/Cas9 



Funding: N. Weintraub and Y. Tang were partially supported by the American Heart Association: GRNT31430008, NIH-AR070029, NIH-HL086555, and NIH-HL134354.

Conflict of Interest: All authors declare that he/she has no conflict of interest.

This article does not contain any studies with human participants performed by any of the authors.


  1. 1.
    Mendell JR, Shilling C, Leslie ND et al (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71:304–313CrossRefGoogle Scholar
  2. 2.
    Trounson A, Mcdonald C (2015) Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 17:11–22CrossRefGoogle Scholar
  3. 3.
    Cunningham JJ, Ulbright TM, Pera MF et al (2012) Lessons from human teratomas to guide development of safe stem cell therapies. Nat Biotechnol 30:849–857CrossRefGoogle Scholar
  4. 4.
    Chudakov DM, Matz MV, Lukyanov S et al (2010) Fluorescent proteins and their applications in imaging living cells and tissues. Physiol Rev 90:1103–1163CrossRefGoogle Scholar
  5. 5.
    Hong H, Yang Y, Cai W (2011) Imaging gene expression in live cells and tissues. Cold Spring Harb Protoc 2011:pdb top103CrossRefGoogle Scholar
  6. 6.
    Lyons SK, Patrick PS, Brindle KM (2013) Imaging mouse cancer models in vivo using reporter transgenes. Cold Spring Harb Protoc 2013:685–699CrossRefGoogle Scholar
  7. 7.
    Lecoq J, Schnitzer MJ (2011) An infrared fluorescent protein for deeper imaging. Nat Biotechnol 29:715–716CrossRefGoogle Scholar
  8. 8.
    Auld DS, Inglese J (2004) Interferences with luciferase reporter enzymes. In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, JMM C, TDY C, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr, Weidner JR, Wildey MJ, Xia M, Xu X (eds) Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MDGoogle Scholar
  9. 9.
    Wang Y, Zhou M, Wang X et al (2014) Assessing in vitro stem-cell function and tracking engraftment of stem cells in ischaemic hearts by using novel iRFP gene labelling. J Cell Mol Med 18:1889–1894CrossRefGoogle Scholar
  10. 10.
    Filonov GS, Piatkevich KD, Ting LM et al (2011) Bright and stable near-infrared fluorescent protein for in vivo imaging. Nat Biotechnol 29:757–761CrossRefGoogle Scholar
  11. 11.
    Hock AK, Lee P, Maddocks OD et al (2014) iRFP is a sensitive marker for cell number and tumor growth in high-throughput systems. Cell Cycle 13:220–226CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Yue Jin
    • 1
  • Yan Shen
    • 1
  • Neal L. Weintraub
    • 1
  • Yaoliang Tang
    • 1
    Email author
  1. 1.Vascular Biology Center, Medical College of GeorgiaAugusta UniversityAugustaUSA

Personalised recommendations